logo-loader
viewAdalta Ltd

AdAlta manufacturing pulmonary fibrosis candidate in next quarter

AdAlta Limited (ASX: 1AD) CEO Sam Cobb sat down with Christine Corrado at the Biotech Showcase in San Francisco.

AdAlta is an Australian public biotechnology company focused on the development and commercialisation of its i-body technology platform that has generated a pipeline of i-bodies, with an initial focus on treating fibrotic diseases. 

Quick facts: Adalta Ltd

Price: 0.12 AUD

ASX:1AD
Market: ASX
Market Cap: $19.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Adalta Ltd named herein, including the promotion by the Company of Adalta Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

AdAlta capitalises on $5-million raising to progress drug to treat fibrotic...

AdAlta Ltd (ASX:1AD) chief executive officer Sam Cobb updates Proactive Investors on the health-focused company's recent $5 million raising to progress the development of its key AD-214 drug for the treatment of idiopathic pulmonary fibrosis.   Cobb says recent animal trials will...

on 5/6/19

2 min read